The British government’s medicines advisory body has advised against the use of GlaxoSmithKline’s oral cancer drug Tyverb in the National Health Service, dealing a blow to the UK-based pharmaceutical group in its home country.
The National Institute of Health and Clinical Excellence (Nice) on Monday issued a provisional recommendation that Tyverb for advanced breast cancer did not meet its threshold for clinical and cost effectiveness. That recommendation could effectively rule out the UK market for the GSK medicine.
